UnitedHealthcare recently announced its plans to cut prior authorization requirements for 30% of services that previously required insurer approval by the end of 2026.
In the latest update to its Vaccine Administration National Fee Schedule, CMS established three Level II Healthcare Common Procedure Coding System (HCPCS) codes for billing a biosimilar used to treat COVID-19.